Ensysce Biosciences, Inc.

Ensysce Biosciences is a clinical-stage biopharmaceutical company focused on developing prescription medications designed to address pain management while mitigating risks associated with opioid misuse and overdose. The company operates two proprietary technology platforms: Trypsin Activated Abuse Protection (TAAP), which releases active pharmaceutical ingredients only under specific physiological conditions to prevent manipulation, and Multi-Pill Abuse Resistance (MPAR), an overdose protection technology for opioid prodrugs. Its lead program, PF614, is a TAAP-based oxycodone prodrug candidate for severe and chronic pain management, with a combination variant, PF614-MPAR, incorporating nafamostat for overdose protection.

The company's pipeline extends beyond pain management to include PF8001 and PF8026, extended and immediate-release amphetamine prodrugs under development for attention deficit hyperactivity disorder, as well as PF9001 for opioid use disorder treatment. All candidates remain in preclinical or clinical development stages with no marketed products generating revenue.

Ensysce operates as a small-scale organization with seven full-time employees and is headquartered in La Jolla, California. The company was incorporated in Delaware and is publicly traded on Nasdaq, though its market capitalization reflects its early-stage status. The company was founded in 2003.